PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFECTED CHILDREN

PACTG 1020-A：用于 HIV 感染儿童的新型蛋白酶抑制剂 (BMS-232632)

• 批准号: 7605692
• 负责人: William Borkowsky
• 金额: $ 7.9万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605692
• 关键词: Adult; BMS232632; Child; Childhood; Computer Retrieval of Information on Scientific Projects Database; Enrollment; Funding; Grant; Hyperbilirubinemia; Institution; Label; Licensing; Patients; Phase; Protease Inhibitor; Research; Research Personnel; Resistance; Resources; Source; Therapeutic; Toxic effect; United States National Institutes of Health; novel; peptidomimetics

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multicenter phase I/II open-label study of a novel protease inhibitor (BMS-232632) in HIV-1-infected pediatric patients. A wide variety of patients with varying types of therapeutic resistance (excepting noncompliance) are eligible for enrollment. BMS-232632 is a C2-symmetrical azapeptide structurally different from licensed protease inhibitors, which are peptidomimetic. The major toxicity to date in adults has been hyperbilirubinemia. Enrollment into this study continues. Results are not yet available.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 中心，不一定是研究者的机构。 这是一项针对 HIV-1 感染儿科患者的新型蛋白酶抑制剂 (BMS-232632) 的多中心 I/II 期开放标签研究。 具有不同类型治疗耐药性（不依从性除外）的各种患者都有资格参加。 BMS-232632 是一种 C2 对称氮杂肽，其结构不同于已获许可的蛋白酶抑制剂，后者是拟肽。 迄今为止，成人的主要毒性是高胆红素血症。 这项研究的招募工作仍在继续。 结果尚未公布。